{"AGENT-BASED_LEARNING_OF_MATERIALS_DATASETS_FROM_SCIENTIFIC_LITERATURE.pdf": "\ud83d\udcc4 **Summary of the Publication**\nHere is a summary of pages 8-14:\n\nThe document discusses an AI agent-based method for extracting domain-specific information from complex, unstructured text. The method allows users to develop tailored datasets for specific areas without requiring extensive programming skills or NLP knowledge. The results show that the AI agent can learn zero-shot, unlike large language models which are few-shot learners.\n\nThree tools used in the agent-based system are introduced: Chain-of-Verification (CoV), Dataset Search, and CSV Generator. Evaluation metrics such as precision, recall, F1 score, and binary classification accuracy are used to assess the agent's performance.\n\nThe document also lists references to research papers related to the use of large language models in chemistry and materials science. The papers cover topics such as using conversational language models to extract accurate materials data from research papers and developing chatbots for text mining and prediction of MOF synthesis.\n\nA confusion matrix shows that the agent tends to be cautious in its judgments, often predicting \"Not provided\" when unsure rather than incorrectly assigning samples to other categories. Performance comparisons between three models on two relation extraction tasks are presented, with LLM-NERRE outperforming Eunomia on both tasks.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\ud83d\udcdd **Topics Covered in the Publication**\nHere are the scientific topics related to the document summary, output as keywords separated by slashes:\n\n**Natural Language Processing (NLP) / Artificial Intelligence (AI) / Information Extraction / Large Language Models / Chemistry / Materials Science / Text Mining / Machine Learning**\n\nIf you'd like me to condense or reorganize these topics in any way (e.g., grouping related fields), please let me know! For instance, if you prefer a format with fewer, broader categories, here is an alternative:\n\n**Artificial Intelligence (AI) & NLP / Materials Science & Chemistry**\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: new materials\n\ud83d\udca1 **Answer**: Yes \n\ud83d\udd0e **Supporting Sentence**:  This led to the discovery of several novel catalyst compositions for ammonia decomposition, which were experimentally validated against \"state-of-the-art\" ammonia decomposition catalysts and were found to have exceptional low-temperature performance at substantially lower weight loadings of Ru.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: screening algorithms\n\ud83d\udca1 **Answer**: Based on the provided text snippet and the question about new or novel high-throughput or large-scale screening algorithms, methods, or workflows, here's a structured response:\n\n**Answer:** Yes \n\ud83d\udd0e **Supporting Sentence**:  In the present study, we leverage a recently developed high-throughput periodic DFT workflow tailored for MOF structures to construct a large-scale database of MOF quantum mechanical properties.\n\n**Breakdown:**\n\n1. **Does the document mention any new or novel high-throughput or large-scale screening algorithm, methods or workflow?**\n   - **Answer:** Yes\n\n2. **Examples sentence for new high-throughput screening algorithms (as per your request to follow the format exactly):**\n   - Already provided in the question prompt, but for clarity, an example from the document is given below in the answer section.\n\n3. **If there are any, what are the screening algorithms used in the document? Answer either 'Yes' or 'No' followed by a '\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: experimental methodology\n\ud83d\udca1 **Answer**: To address the question effectively, let's break down the steps to identify if the document mentions any new or novel experimental methodology and to extract screening algorithms used in the document based on the provided example sentences.\n\n### Step 1: Identify Novel Experimental Methodology\n- **Task**: Determine if the document introduces a new or novel experimental methodology.\n- **Examples Provided**:\n  1. \"The current work presents a novel modified battery module configuration employing two-layer nanoparticle enhanced phase change materials (nePCM)\"\n  2. \"A novel synthesis of new antibacterial nanostructures based on Zn-MOF compound: design, characterization and a high performance application\"\n- **Analysis**: Both example sentences explicitly mention the introduction of something \"novel\" in the context of experimental methodologies or syntheses.\n- **Action for Your Document**:\n  - Read through your document's abstract and body to identify any sentences or sections that explicitly mention \"novel,\" \"new,\" \"innovative,\" or similar terms in the context of experimental methodologies.\n  - If found, extract these sentences as they indicate novel experimental methodologies.\n\n### Step 2: Identify Screening Algorithms\n- **Task**: Determine if screening algorithms are mentioned and extract relevant sentences.\n- **Example Sentence for Context (Not Directly Related to Screening Algorithms but Part of the Task)**:\n  3. \"This study revealed the therapeutic potency of a novel hybrid peptide, and supports the use of rational design in development of new antibacterial agents\"\n- **Analysis for Screening Algorithms**:\n  - The provided example sentences do not directly mention screening algorithms. However, to fulfill this task:\n  - **Action for Your Document**:\n    - Systematically search your document for keywords related to screening algorithms such as \"screening,\" \"algorithm,\" \"computational screening,\" \"high-throughput screening,\" etc.\n    - If any sentence mentions the use of a screening algorithm, extract it in its entirety without modifications.\n\n### Response Format\n- **For Novel Experimental Methodology**:\n  - **Yes\n\ud83d\udd0e **Supporting Sentence**: ** [Exact Sentence(s) from Document]\n  - **No\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: ML algirothms\n\ud83d\udca1 **Answer**: Yes \n\ud83d\udd0e **Supporting Sentence**:  The emergence of Large Language Models (LLMs) or foundation models, shows a great promise in tackling these complex NLP tasks [ 7,12\u201314].\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: models\n\ud83d\udca1 **Answer**: Yes \n\ud83d\udd0e **Supporting Sentence**:  Chain-of-verification reduces hallucination in large language models.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: funding\n\ud83d\udca1 **Answer**: No\n\ud83d\udd0e **Supporting Sentence**: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: material datasets\n\ud83d\udca1 **Answer**: No\n\ud83d\udd0e **Supporting Sentence**: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: drug formulations explored\n\ud83d\udca1 **Answer**: No\n\ud83d\udd0e **Supporting Sentence**: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: lead small-molecule drug candidates\n\ud83d\udca1 **Answer**: No\n\ud83d\udd0e **Supporting Sentence**: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: clinical trials\n\ud83d\udca1 **Answer**: No\n\ud83d\udd0e **Supporting Sentence**: None \n\n(Rationale: The provided text snippet appears to be a list of references and citations, with no explicit mention of clinical trials in the context of the document itself. While some of the cited works may involve clinical trials, as indicated by reference [24] mentioning \"human feedback\" which could imply a trial setting, there is no direct sentence within the provided text that confirms the presence of clinical trials within the document's content.)\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: **LLM Self-Reference & Meta-AI**\n\ud83d\udca1 **Answer**: Yes \n\ud83d\udd0e **Supporting Sentence**:  This tool aims at obtaining the most relevant context (sentences) from the papers to a given input query, using OpenAI\u2019s text-ada-002 embeddings to represent texts as high dimensional vectors.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501", "cell_penetration_of_oxadiazole_containing_macrocycles.pdf": "\ud83d\udcc4 **Summary of the Publication**\nHere is a global summary of the document:\n\nThe study investigates the cell-penetrating ability of oxadiazole-containing (Odz) peptides, which are cyclic peptides with embedded heterocyclic functionalities. The authors employed various assays to investigate the cell penetration of Odz peptides and found that they can be highly cell-penetrant depending on the position of specific side chains and the chloroalkane tag. However, despite observing high cell penetration, low passive permeability was observed in experiments with artificial membranes.\n\nThe study highlights the importance of structural features such as lipophilicity and conformation on cell penetration and provides insights into the design of more effective cell-penetrating peptides. The authors found that incorporating lipophilic residues such as leucine and phenylalanine at specific positions increased passive membrane permeability and cell penetration, while replacing these residues with lysine resulted in lower cell penetration.\n\nThe study also investigated the cell penetration mechanism of Odz macrocycles and found that conformation is an important factor affecting relative exposure of hydrogen bond donors and acceptors, overall polar surface area, and ultimately extent of cell penetration. The results suggest that cell penetration may not be through passive permeation but possibly through active transport.\n\nOverall, the study provides a framework for designing cell-penetrant cyclic peptides and highlights the importance of considering the structure and modification of cyclic peptides in understanding their cell penetration mechanism.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\ud83d\udcdd **Topics Covered in the Publication**\nHere are the scientific topics related to the document, output as keywords separated by a slash (/):\n\n**Cell-Penetrating Peptides / Cyclic Peptide Design / Membrane Permeability / Bioorganic Chemistry / Structural Biology / Active Transport Mechanisms / Pharmaceutical Biotechnology / Peptide Engineering**\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: new materials\n\ud83d\udca1 **Answer**: No\n\ud83d\udd0e **Supporting Sentence**: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: screening algorithms\n\ud83d\udca1 **Answer**: NA\n\ud83d\udd0e **Supporting Sentence**: None \n\nThere is no mention of new or novel high-throughput or large-scale screening algorithms, methods, or workflows in the provided document snippet. The text appears to be a list of references related to chemistry and pharmacology, without any description of innovative screening approaches.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: experimental methodology\n\ud83d\udca1 **Answer**: Yes \n\ud83d\udd0e **Supporting Sentence**:  This generates oxadiazole-grafted (Odz) macrocycles with high passive permeability as measured using the parallel artificial membrane permeability assay (PAMPA) (Fig. 1 c).\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: ML algirothms\n\ud83d\udca1 **Answer**: No\n\ud83d\udd0e **Supporting Sentence**: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: models\n\ud83d\udca1 **Answer**: Yes \n\ud83d\udd0e **Supporting Sentence**:  We noted that the calculated solution structure of compound 6a had many violations of ROE-derived distance restraints, suggesting that multiple interconverting conformations are present.\n\nExplanation:\nThe document mentions a specific method for calculating the solution structure of compound 6a, which involves analyzing ROE (Rotating-frame Overhauser Effect)-derived distance restraints. The fact that this analysis revealed \"many violations\" and suggested the presence of \"multiple interconverting conformations\" implies a nuanced and potentially novel approach to understanding the structural dynamics of this compound. This method is not explicitly stated as new, but its application in this context and the insights it provides suggest an innovative or specialized workflow in structural biology or chemistry.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: funding\n\ud83d\udca1 **Answer**: No\n\ud83d\udd0e **Supporting Sentence**: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: material datasets\n\ud83d\udca1 **Answer**: NA\n\ud83d\udd0e **Supporting Sentence**: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: drug formulations explored\n\ud83d\udca1 **Answer**: No\n\ud83d\udd0e **Supporting Sentence**: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: lead small-molecule drug candidates\n\ud83d\udca1 **Answer**: No\n\ud83d\udd0e **Supporting Sentence**: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: clinical trials\n\ud83d\udca1 **Answer**: No\n\ud83d\udd0e **Supporting Sentence**: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: **Artificial Intelligence/Machine Learning (Specifically, Large Language Models - LLMs)**\n\ud83d\udca1 **Answer**: No\n\ud83d\udd0e **Supporting Sentence**: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501", "ansari-white-2023-serverless-prediction-of-peptide-properties-with-recurrent-neural-networks.pdf": "\ud83d\udcc4 **Summary of the Publication**\nHere is a brief summary of each reference:\n\n(55) Keras library developed by Fran\u00e7ois Chollet in 2015.\n\n(56) TensorFlow deep learning framework first released in 2015.\n\n(57) Conference paper on generating text using recurrent neural networks (RNNs).\n\n(58) Article on generating focused molecule libraries for drug discovery using RNNs.\n\n(59) Research article on predicting HLA-peptide binding using bidirectional LSTMs and multiple head attention mechanisms.\n\n(60) Foundational paper on long short-term memory (LSTM) architecture.\n\n(61) Article exploring active learning and meta-learning for iterative peptide design.\n\n(62) Classic paper on interpreting ROC curves in machine learning.\n\n(63) Reference to the Adam stochastic optimization algorithm.\n\n(64) Early paper on density estimation using kernel methods.\n\n(65) Article presenting squeeze-and-excitation mechanisms for improving deep neural networks.\n\n(66) Conference paper exploring identity mappings in residual networks.\n\n(67) Article on aggregating multi-scale context information using dilated convolutions.\n\n(68) Article using deep learning to design proteins and peptides.\n\n(69) Preprint reimplementing the Unirep protein engineering method using JAX library.\n\n(70) Foundational paper on random forests, an ensemble learning method.\n\n(71) Article using machine learning to design non-hemolytic antimicrobial peptides.\n\n(72) Article exploring bioinformatics approaches for predicting protein solubility in E. coli.\n\n(73) Conference paper presenting model cards for reporting model performance.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\ud83d\udcdd **Topics Covered in the Publication**\nBased on the provided summary, here are the extracted scientific topics in the requested format (keywords separated by '/'):\n\n**Output:** \n`Machine Learning / Deep Learning / Artificial Neural Networks / Natural Language Processing (Text Generation) / Drug Discovery / Bioinformatics / Protein Engineering / Computational Biology / Ensemble Learning`\n\n**Brief Rationale for each topic:**\n\n* **Machine Learning**: References to ROC curves, Adam optimization, and ensemble learning methods.\n* **Deep Learning**: Mentions of TensorFlow, Keras, RNNs, LSTMs, residual networks, and deep neural networks.\n* **Artificial Neural Networks**: Specific architectures like RNNs, LSTMs, and discussions on improving deep neural networks.\n* **Natural Language Processing (Text Generation)**: Reference to generating text using RNNs.\n* **Drug Discovery**: Generating focused molecule libraries for drug discovery.\n* **Bioinformatics**: Predicting HLA-peptide binding, protein solubility in E. coli, and designing proteins/peptides.\n* **Protein Engineering**: Designing proteins and peptides, including non-hemolytic antimicrobial peptides and the Unirep method.\n* **Computational Biology**: Overarching theme connecting bioinformatics, protein engineering, and drug discovery through computational methods.\n* **Ensemble Learning**: Specific mention of random forests.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: new materials\n\ud83d\udca1 **Answer**: No\n\ud83d\udd0e **Supporting Sentence**: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: screening algorithms\n\ud83d\udca1 **Answer**: Yes \n\ud83d\udd0e **Supporting Sentence**:  We performed a large-scale screening of fast-growing strains with 180 strains isolated from 22 ponds located in a wide geographic range from the tropics to cool-temperate. **(NO, THIS SENTENCE IS NOT IN THE PROVIDED DOCUMENT, I APOLOGIZE FOR THE MISTAKE)**\n\n\nCorrect Answer:\nNA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: experimental methodology\n\ud83d\udca1 **Answer**: No \n\ud83d\udd0e **Supporting Sentence**:  NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: ML algirothms\n\ud83d\udca1 **Answer**: Yes \n\ud83d\udd0e **Supporting Sentence**:  TheoutputfromtheLSTMlayeristhenconcatenated withtherelativefrequency ofeachaminoacidintheinputsequences. Thischoiceispartiallybasedonourearlierwork,61andhelpswithimproving modelperformance. Theconcatenated outputisthennormalized andfedtoadropout layerwitharateof10%,followed byadense neuralnetwork withaReLUactivation function. Thisisrepeated threetimes,andthefinalsingle-node denselayeruses \n\n(Note: While the document does not introduce a completely novel algorithm, it describes a custom architecture and setup for deep learning models, specifically tailored for the task at hand, which involves concatenating LSTM output with amino acid frequency, normalization, dropout layers, and dense neural networks. This could be interpreted as developing or proposing a new model architecture for the specific application, rather than introducing a fundamentally new machine learning or deep learning algorithm like ELM or ionbot in the example sentences.)\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: models\n\ud83d\udca1 **Answer**: Yes \n\ud83d\udd0e **Supporting Sentence**:  HAPPENN usesnormalized features selected bySVMandensemble ofRandom Forests, which arefedtoadeepneuralnetwork withbatchnormalization and regression classifier.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: funding\n\ud83d\udca1 **Answer**: No\n\ud83d\udd0e **Supporting Sentence**:  The authors thank Mohammad Madani at the University of\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: material datasets\n\ud83d\udca1 **Answer**: No\n\ud83d\udd0e **Supporting Sentence**: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: drug formulations explored\n\ud83d\udca1 **Answer**: No\n\ud83d\udd0e **Supporting Sentence**: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: lead small-molecule drug candidates\n\ud83d\udca1 **Answer**: No\n\ud83d\udd0e **Supporting Sentence**: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 **Question**: clinical trials\n\ud83d\udca1 **Answer**: NA\n\ud83d\udd0e **Supporting Sentence**: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501"}